- Sort by Relevance
- Display 15 Products per page
Published: May 1, 2006 | Price: $3,500.00 – $7,000.00
CRO is a need-to know practice in pharmaceutical marketing today; but information is not always easy to find. This second edition of Kalorama’s best-selling look at the clinical contract research industry provides the key information competitors need to navigate the complexities and costs of clinical research in the drug development process. In addition to a comprehensive discussion of the market and regulatory environment, the report details: the size and nature of the drug research pipeline, the size and growth of...Published: April 1, 2006 | Price: $3,900.00 – $7,800.00
This completely updated edition of Kalorama’s comprehensive and indispensable report covers the breadth of traditional IVD testing. The report contains complete market statistics and analysis for all areas of IVD, including: Point-of-Care Clinical Chemistry Immunoassays Molecular Assays Hematology Coagulation Microbiology and Virology Blood Banking Histology and Cytology Market size, growth, share, and geographic distribution, as well as trends in technology development, regulatory and reimbursement issues, clinical care, and business environments are discussed. Projections are made through 2010. This new 1,000-page...Published: April 1, 2006 | Price: $3,500.00 – $7,000.00
Adjunctive therapies are not only vital to the success of cancer treatments, enhancing compliance and outcomes, but they are also a dynamic area of research and development in a variety of disciplines from drug delivery to biologics. It also happens to be the largest portion of the overall cancer therapeutics market. This report provides the reader with a comprehensive analysis of the worldwide market for therapeutics to treat and manage symptoms in cancer patients. Market information, including market size and...Published: April 1, 2006 | Price: $2,500.00 – $7,000.00
The landscape of generic companies is changing: their relative might in the industry is increasing and the product lines their offering are growing in depth and breadth. Strong growth in the sector has come not only from more aggressive tactics and better acceptance in the clinical and consumer population, but by the loss of patent protection in the past few years of some huge-name drugs, including Prozac, Zocor, Prilosec, Prevacid, Sporanox, Evista, Flovent, Claritin, Allegra, Diflucan, Zofran, Zoloft, and Pravachol....Published: March 1, 2006 | Price: $3,500.00 – $7,000.00
There are hundreds of drugs in Phase III clinical trials, of which almost 200 of them may gain market approval from the FDA in the coming 5 years. Which drugs will make it and how these drugs impact existing pharmaceutical markets in terms of overall size and competitive share is one of the most difficult forecasting projects in market research. In this nearly 500-page analysis, Kalorama Information has compiled all the relevant information about the candidates, their value, and their...Published: March 1, 2006 | Price: $3,500.00 – $7,000.00
The strategic interplay of of HIV/AIDS diagnostics and therapeutics is one of the most complex that the healthcare industry has ever seen. In order to cope with the challenges and opportunities of HIV/AIDS, companies must think on a global basis, and in addition to the basic pathology and complications of HIV/AIDS, there are societal and ethical pressures, geopolitical factors, and evolving marketplace disruptions. For the development of a coherent strategy in this therapeutic area, companies must clearly focus on three...Published: March 1, 2006 | Price: $3,000.00 – $6,000.00
This report on the U.S. market for over-the-counter (OTC) pediatric medications presents an in-depth analysis of the performance of non-prescription pediatric drugs and other selected pediatric healthcare products in the marketplace. The analysis captures the performance of the market players, categories, and leading brands in terms of revenue growth and volume growth in several categories of medication, including cough/cold allergy sinus products; first aid products; internal analgesic products, and other pediatric products (chest rubs, nasal products and bedwetting remedies). In...Published: February 18, 2006 | Price: $2,995.00 – $5,990.00
The reinvigorated market for medical imaging systems employing x-rays has undoubtedly been propelled by the explosion of digital technology. But also, the expanded role of imaging modalities in a whole host of clinical applications from trauma to cancer to cardiology has increased the profile of radiography while enabling computer technologies expand the usefulness of traditional x-ray techniques. This report analyzes the current and potential world market for medical x-ray systems, including several distinct imaging modalities and applications both traditional and...Published: February 18, 2006 | Price: $2,200.00 – $5,990.00
Biopharmaceutical research and development is sure to dramatically increase the number of injectable drugs coming to market over the next few years. While advanced drug delivery techniques continue to hold promise for unique methods of administration, the traditional injection is still the dominant paradigm. However, the staggering costs and intransigent safety problems associated with sharps, along with consumer demand and the move to alternate-site care, are pushing for alternatives to traditional needles and syringes faster than advanced delivery technologies can...Published: February 1, 2006 | Price: $1,995.00 – $7,800.00
This report provides the reader with a comprehensive analysis of the domestic and international markets involving pharmaceuticals to treat skin diseases and disorders. This edition of Worldwide Market for Prescription Dermatologic Drugs is the fifth time Kalorama Information has comprehensively studied the dermatology markets. As is the case with each new edition, Kalorama completely re-evaluated the market from the ground up, and in addition to the usual primary interviewing of industry participants, clinicians, and regulators, we also conducted scores of...Published: February 1, 2006 | Price: $3,000.00 – $6,000.00
The private label over-the-counter (OTC) market has been gaining ground rapidly over the past five years. The private label sector has shed its image of being a ‘me-too’ version of national brands and worked toward offering quality and innovation at an economical price. With benefits for consumers, retailers, and manufacturers, private label healthcare should experience solid growth through the end of the decade. This report on the U.S. market for OTC private label products presents an in-depth analysis of the...Published: January 1, 2006 | Price: $995.00 – $5,990.00
With the mapping of the human genome and the concomitant explosion of proteomics, a steady stream of biopharmaceuticals have been launched—recombinant therapeutic proteins, monoclonal antibody-based products used for therapeutic or in vivo diagnostic purposes, and nucleic acid-based products. As the rate of regulatory approval for biopharmaceuticals increases, the number of products reaching the market will impose unprecedented demands on the industry’s biomanufacturing capacity. Whether or not this will create a biomanufacturing bottleneck is a hotly debated issue in the industry....Published: January 1, 2006 | Price: $2,995.00 – $5,990.00
The field of biotechnology instrumentation has been an expanding one ever since the emergence of the Human Genome Project 20 years ago. Although the filed certainly existed prior to that point in time, it was the Human Genome Project with its major access to key universities, national laboratories, and government funding sources that gave great acceleration to the field. There are several technologies applicable to genomic and proteomic analysis, all of which have become important to the nature of the...Published: January 1, 2006 | Price: $2,995.00 – $5,990.00
In the Spring of 2003, Kalorama published its first report on Outsourcing in Drug Discovery. Since then, so much has changed, the use of the term "2nd Edition" hardly seems appropriate. This new study involved completely re-examining the market from the ground up. This new report is designed to make readers aware of the enormous changes that are taking place in the drug discovery outsourcing market, and the forces that are shaping the sector. It presents viewpoints from both customers...Published: January 1, 2006 | Price: $3,500.00 – $7,000.00
The U.S. long-term care industry experienced strong growth from 1999 through 2004 and this growth is expected to continue through the end of the decade. Indeed, the aging of the U.S. population will push unprecedented demand for all forms of long-term care, but ongoing cost containment issues continue to pressure both private and public managed care organizations and make competition in this dynamic environment challenging. This comprehensive study from Kalorama Information details four segments of the long-term care industry, including:...